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Functional inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene is the cause of the familial
VHL disease and most sporadic renal clear-cell carcinomas (RCC). pVHL has been shown to play a role in the
destruction of hypoxia-inducible factor  (HIF-) subunits via ubiquitin-mediated proteolysis and in the
regulation of fibronectin matrix assembly. Although most disease-causing pVHL mutations hinder the regu-
lation of the HIF pathway, every disease-causing pVHL mutant tested to date has failed to promote the
assembly of the fibronectin matrix, underscoring its potential importance in VHL disease. Here, we report that
a ubiquitin-like molecule called NEDD8 covalently modifies pVHL. A nonneddylateable pVHL mutant, while
retaining its ability to ubiquitylate HIF, failed to bind to and promote the assembly of the fibronectin matrix.
Expression of the neddylation-defective pVHL in RCC cells, while restoring the regulation of HIF, failed to
promote the differentiated morphology in a three-dimensional growth assay and was insufficient to suppress
the formation of tumors in SCID mice. These results suggest that NEDD8 modification of pVHL plays an
important role in fibronectin matrix assembly and that in the absence of such regulation, an intact HIF
pathway is insufficient to prevent VHL-associated tumorigenesis.
von Hippel-Lindau (VHL) disease is a rare familial cancer
syndrome that displays a dominant pattern of inheritance (14,
21). Individuals with VHL disease develop multiple tumors in
numerous organs, including the retina, cerebellum, spine, pan-
creas, adrenal glands, the endolymphatic sac of the inner ear,
and the kidney (14, 21). Although VHL disease occurs in only
1 out of 36,000 individuals, a vast majority of sporadic renal
clear-cell carcinomas (RCC) are associated with a biallelic loss
of VHL (14, 21).
The VHL protein (pVHL) is a component of an E3 ubiq-
uitin ligase complex, VEC, comprising elongins B and C, Rbx1,
and Cul2 (14). VEC binds and targets specifically prolyl-hy-
droxylated  subunits of hypoxia-inducible factor 1 (HIF-1),
HIF-2, and HIF-3 for polyubiquitylation (2, 10, 12, 19, 20, 22).
The hydroxylation of HIF- by the newly identified class of
prolyl-hydroxylases occurs on conserved proline residues
within the oxygen-dependent degradation domain (ODD) in
the presence of oxygen and iron (5, 10–12). The polyubiquitin-
tagged HIF- subunits are subsequently captured by the 26S
proteasome for degradation. Thus, under hypoxia, HIF- sub-
units remain unhydroxylated and consequently escape ubiq-
uitin-mediated proteolysis. The HIF- subunits bind to consti-
tutively stable HIF- (also known as ARNT [aryl-hydrocarbon
receptor nuclear translocator]) subunits, forming an active het-
erodimeric HIF transcription factor that binds to the hypoxia-
responsive elements in the promoters of numerous hypoxia-
inducible genes, triggering the physiologic responses to
hypoxia. Tumor cells devoid of functional pVHL produce in-
ordinate amounts of HIF-regulated hypoxia-inducible genes,
such as vascular endothelial growth factor, irrespective of the
ambient oxygen tension (14). The expression of this and other
hypoxia-inducible angiogenic factors likely accounts for the
vascular phenotype of VHL-associated tumors.
pVHL also binds directly to fibronectin (1, 9, 23). More
importantly, all disease-associated pVHL mutants examined to
date exhibit reduced or undetectable binding to fibronectin
(21). The physical interaction of fibronectin with the wild-type
pVHL has been linked to the proper assembly of an extracel-
lular fibronectin matrix (23). Lieubeau-Teillet and coworkers
demonstrated that RCC cells lacking pVHL grow as tightly
packed spheroids in a three-dimensional growth assay, indica-
tive of an undifferentiated phenotype (17). In contrast, RCC
cells reconstituted with pVHL form loose aggregates which,
upon microscopic and ultrastructural examination, exhibit ev-
idence of epithelial differentiation, such as trabecular and tu-
bular structures (17). These observations correlate with differ-
ences in fibronectin matrix deposition, with pVHL-expressing
cells producing appreciable fibronectin arrays in the extracel-
lular space, suggesting that fibronectin is actively involved in
the growth and differentiation of cells through the interaction
with pVHL (17). Furthermore, Davidowitz and colleagues
demonstrated that pVHL-expressing RCC cells grown on ex-
tracellular matrix (ECM) differentiate into organized epithelial
monolayers, whereas pVHL-deficient cells are branched and
disorganized and fail to arrest under high cell density (4). The
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reintroduction of pVHL in RCC cells markedly increases the
expression of hepatocyte nuclear factor 1, a transcription
factor and global activator of proximal tubule-specific genes in
the nephron (4). These observations strengthen the notion that
pVHL plays a causal role in renal cell differentiation and
mediates growth arrest through the integration of cell-ECM
signals.
Here, we show that pVHL becomes covalently conjugated by
NEDD8. This modification is not required for the E3 activity
of VEC to target HIF- for ubiquitylation. However, a
nonneddylateable pVHL mutant failed to bind to and promote
the assembly of fibronectin. The expression of the neddylation-
defective pVHL in RCC cells, while restoring the regulation of
HIF, failed to promote the differentiated morphology in a
three-dimensional growth assay and was insufficient to sup-
press the formation of tumors in SCID mice. Thus, the ned-
dylation-defective pVHL mutant clearly separates the func-
tions of E3 ligase activity and fibronectin matrix assembly. The
study below demonstrates that NEDD8 modification of pVHL
plays an important role in the proper assembly of fibronectin
and that in the absence of such regulation, an intact HIF
pathway is insufficient to prevent tumorigenesis.
MATERIALS AND METHODS
Cells. 786-O RCC subclones stably transfected to produce wild-type pVHL
[pVHL(WT)] or pVHL(RRR) or transfected with empty plasmid were previ-
ously described (13, 18). Osteosarcoma U2OS and prostate carcinoma PC-3 cells
were obtained from the American Type Culture Collection (Rockville, Md.) and
maintained in Dulbecco’s modified Eagle’s medium supplemented with 10%
heat-inactivated fetal bovine serum (Sigma) at 37°C in a humidified 5% CO2
atmosphere.
Antibodies. Monoclonal anti-Gal4 (DBD; RK5C1) and anti-hemagglutinin
(HA) (12CA5) antibodies were from Santa Cruz and Boehringer, respectively.
Monoclonal anti-T7 antibody was from Novagen (Madison, Wis.). Polyclonal
anti-GLUT1 and monoclonal anti-Cul2 antibodies were from Alpha Diagnostics
and Zymed, respectively. Polyclonal anti-fibronectin antibody was from Calbio-
chem. Monoclonal anti-pVHL antibody (IG32) was previously described (13).
Plasmids. Mammalian expression plasmids pRc-CMV-HA-VHL(WT) and
pRc-CMV-HA-VHL(C162F) were described previously (18). pRc-CMV-HA-
VHL(RRR), -(KRR), -(RKR), -(RRK), and -(K159E) and pRc-CMV-HA-
VHL(R200K) and -(R210K), which are in the background of pVHL(RRR), were
generated the same way, by using a Stratagene site-directed mutagenesis kit
according to the manufacturer’s instructions. Expression plasmids pcDNA3-T7-
NEDD8, pcDNA3-T7-NEDD8GG, and pcDNA3-T7-SUMO were described
previously (24). All plasmids were confirmed by direct DNA sequencing.
Immunoprecipitation and immunoblotting. Immunoprecipitation and West-
ern blotting were performed as described previously (23). In brief, cells were
lysed in EBC buffer (50 mM Tris [pH 8.0], 120 mM NaCl, 0.5% NP-40) supple-
mented with protease and phosphatase inhibitors (Roche). Immunoprecipitates,
immobilized on protein A-Sepharose (Amersham Biosciences, Uppsala, Swe-
den), were washed five times with NETN buffer (20 mM Tris [pH 8.0], 120 mM
NaCl, 1 mM ETDA, 0.5% NP-40), eluted by boiling in sodium dodecyl sulfate
(SDS)-containing sample buffer, and separated by SDS-polyacrylamide gel elec-
trophoresis (PAGE).
In vitro ubiquitylation assay. An in vitro ubiquitylation assay was performed
as previously described (22). [35S]methionine-labeled reticulocyte lysate HA-
HIF1-[ODD] translation products (4 l) were incubated in RCC 786-O S100
extracts (100 to 150 g), prepared as previously described (22), supplemented
with 8 g of ubiquitin/l (Sigma), 100 ng of ubiquitin-aldehyde/l (BostonBio-
chem, Cambridge, Mass.), and an ATP-regenerating system (20 mM Tris [pH
7.4], 2 mM ATP, 5 mM MgCl2, 40 mM creatine phosphate, 0.5 g of creatine
kinase/l) in a reaction volume of 20 to 30 l for 1.5 h at 30°C.
Purification of HIF prolyl-hydroxylase. Extracts containing enriched prolyl-
hydroxylases were purified from rabbit reticulocyte lysate as previously described
(11).
Fibronectin ELISA. The enzyme-linked immunosorbent assay (ELISA) for
measuring the deposition of fibronectin was performed as described previously
(23).
Immunofluorescence microscopy. Fibronectin immunofluorescence micros-
copy was performed as described previously (23). Briefly, 1 105 RCC cells were
seeded on sterilized coverslips in six-well plates and grown for 5 days. Cells on
coverslips were washed three times in 1 phosphate-buffered saline (PBS) prior
to ethanol fixation at 20°C for 30 min. Fixed cells were hybridized with poly-
clonal anti-fibronectin antibody at 4°C for 16 h. Cells were washed twice in 1
PBS and then hybridized with rhodamine-conjugated goat anti-rabbit antibody
for 1 h at room temperature. Cells were washed twice in 1 PBS, rinsed briefly
with DAPI (4,6-diamidino-2-phenylindole) stain at 1:1,000 in 1 PBS, and
mounted on glass slides with glycerol-PBS (1:1). Fluorescence images were
captured on a Carl Zeiss Axiovert 200 microscope imaging system.
Three-dimensional spheroid assay. Multicellular spheroids were prepared as
described previously (17). Briefly, 24-well tissue culture plates (Nunc) were
coated with 250 l of prewarmed 1% SeaPlaque agarose (Cambrex BioScience
Rockland, Inc.) in serum-free medium. A total of 105 cells in 1 ml of Dulbecco’s
modified Eagle’s medium supplemented with 10% fetal calf serum was added to
the agarose-coated wells. The cells were grown in a humidified 5% CO2 atmo-
sphere at 37°C for 72 h. Digital images were taken at 50 magnification.
SCID mouse xenograft assay. Multiple 786-O RCC subclones expressing
pVHL(WT), pVHL(RRR), or plasmid alone were grown to approximately 90%
confluence in a humidified 5% CO2 atmosphere at 37°C. The cells were har-
vested with 0.25% trypsin–1 mM EDTA solution. Doses of 5  106 cells in 50 l
of 1 PBS were injected intramuscularly into the left hind leg of SCID male mice
(Charles River Lab). Tumor growth was assessed and measured weekly by
carefully passing the tumor-bearing leg through a series of holes of decreasing
diameter (0.5-mm decrements) in a plastic rod.
RESULTS
NEDD8 conjugates to pVHL in vivo. During a previous study
examining the role of NEDD8 conjugation of Cul2 in the E3
ligase activity of VEC (24), it was found that pVHL was also
modified by NEDD8 (Fig. 1). U2OS osteosarcoma cells were
transiently transfected with a mammalian expression plasmid
encoding HA-pVHL with or without a plasmid encoding T7-
NEDD8. Cells were lysed and immunoprecipitated with either
anti-HA or anti-T7 antibody and immunoblotted with anti-T7
or anti-HA antibody (Fig. 1A and B). A protein migrating
approximately 40 kDa was observed in cells transfected with
both HA-pVHL- and T7-NEDD8-encoding plasmids (Fig. 1A,
lanes 3 and 8; Fig. 1B, lane 2). This protein contains both HA
and T7 epitopes and was absent in cells transfected with HA-
pVHL alone or T7-NEDD8 alone (Fig. 1A, lanes 2, 4, 7, and
9; Fig. 1B, lane 1). It should be noted that HA-pVHL inter-
acted with the endogenous NEDD8 (Fig. 1A, lane 8; Fig. 1B,
lanes 1 and 2) or T7-NEDD8 interacted with the endogenous
pVHL (Fig. 1A, lane 9). pVHL is known to bind elongin C, but
this is a noncovalent interaction and hence dissociates under
denaturing conditions, as in SDS-PAGE. Thus, although HA-
pVHL coprecipitated T7-elongin C (Fig. 1A, lane 5), it did not
form a stable covalent complex as seen between HA-pVHL
and T7-NEDD8. These observations suggest that the 40-kDa
protein is HA-pVHL covalently modified by T7-NEDD8.
These results suggest that a minor fraction of pVHL is conju-
gated with NEDD8.
We next asked whether pVHL modification was specific to
NEDD8. U2OS cells were transfected with plasmids encoding
HA-pVHL and the N-terminal T7-tagged ubiquitin-like pro-
teins (Ubl) SUMO, elongin B, NEDD8, and NEDD8 missing
the essential C-terminal glycine-glycine residues required for
conjugation (NEDD8GG) (Fig. 1C). The cells were lysed and
immunoprecipitated and immunoblotted with an anti-HA an-
tibody. A slower-migrating form of pVHL of approximately 40
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FIG. 1. pVHL is conjugated by NEDD8. (A and B) U2OS cells were transfected with plasmids encoding HA-pVHL, T7-NEDD8, and
T7-elongin C or with empty vector (MOCK). The cells were lysed and immunoprecipitated with anti-HA or anti-T7 antibodies. Bound proteins
were resolved by SDS-PAGE and immunoblotted with an anti-T7 (A) or anti-HA (B) antibody. (C) U2OS cells were transfected with plasmids
encoding the indicated ubiquitin-like molecules or empty vector, with (left panel) or without (right panel) a plasmid encoding HA-pVHL. The cells
were lysed and immunoprecipitated with anti-HA (left panel) or anti-T7 (right panel) antibody. Bound proteins were resolved by SDS-PAGE and
immunoblotted with the indicated antibodies. (D) Endogenous association of pVHL and NEDD8. Prostatic PC-3 cancer cells were lysed and
immunoprecipitated with an anti-pVHL antibody. Bound proteins were resolved by SDS-PAGE and transferred to a polyvinylidene difluoride
membrane. The membrane was cut into three sections, and each section was immunoblotted with the indicated antibody. *, uncharacterized
protein; IP, immunoprecipitated; IB, immunoblotted.
VOL. 24, 2004 NEDD8 IN MATRIX ASSEMBLY AND TUMOR DEVELOPMENT 3253
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kDa was observed only in cells transfected with both HA-
pVHL and full-length T7-NEDD8 (Fig. 1C, lane 4). Elongin B,
like elongin C, binds pVHL noncovalently. Thus, under the
denaturing condition of SDS-PAGE, a slower-migrating form
of pVHL was not observed. Furthermore, as an internal neg-
ative control, T7-NEDD8GG failed to associate with pVHL
(Fig. 1C, lane 5). The expression of T7-tagged ubiquitin-like
proteins in cells was confirmed by Western blotting (Fig. 1C,
lanes 6 to 10). These results suggest that pVHL is covalently
modified by NEDD8.
To address whether the neddylation of pVHL occurs under
physiologic conditions, the PC-3 prostatic cell line was lysed
and immunoprecipitated with a monoclonal anti-pVHL anti-
body. The upper pVHL of around 40 kDa reacted with both
anti-pVHL antibody and anti-NEDD8 antibody (Fig. 1D). A
similar result was also observed in the 293 embryonic kidney
cell line (data not shown). In control experiments, we con-
firmed that the anti-NEDD8 antibody recognized NEDD8 but
not other ubiquitin-like proteins such as SUMO, elongin B,
and ubiquitin (24; data not shown).
NEDD8 conjugation of pVHL is dependent on lysine 159.
Analogous to the ubiquitin pathway, the neddylation of pro-
FIG. 2. NEDD8 conjugation of pVHL is dependent on lysine 159. (A and B) U2OS cells were transfected with plasmids encoding T7-NEDD8
and the indicated HA-pVHL. The cells were lysed and immunoprecipitated with an anti-HA antibody. Bound proteins were resolved by
SDS-PAGE and immunoblotted with an anti-HA antibody. *, uncharacterized modification of pVHL; IP, immunoprecipitated; IB, immunoblotted.
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teins involves the concerted actions of the NEDD8-activating
enzyme (E1 [APP-BP1/Uba3]) and a NEDD8-conjugating en-
zyme (E2). Neddylation occurs invariably on lysine residues.
pVHL contains three potential NEDD8 acceptor sites at ly-
sines 159, 171, and 196. We tested whether neddylation indeed
occurs on these sites by generating a triple K (lysine) to R
(arginine) substitution mutant, pVHL(RRR). As a specificity
control, we generated pVHL(RRR) mutants with R200K and
R210K substitutions. Plasmids encoding these mutants were
transfected into U2OS cells in combination with T7-NEDD8
(Fig. 2A). pVHL(RRR), as well as pVHL(R200K) and
pVHL(R210K), failed to become neddylated (Fig. 2A), sug-
gesting that the neddylation of pVHL occurs specifically on
lysines 159, 171, and/or 196.
To address the question of which of the three lysines was
essential for neddylation, we generated three double K-to-R
FIG. 3. pVHL(RRR) ubiquitylates HIF- subunits and regulates the expression of HIF-targeted GLUT1. (A) 786-O cells stably transfected
with plasmids encoding pVHL(WT), pVHL(C162F), or pVHL(RRR) or empty plasmid (MOCK) were radiolabeled with [35S]methionine, lysed,
and immunoprecipitated with an anti-HA antibody. Bound proteins were resolved by SDS-PAGE and visualized by autoradiography. (B) The
indicated 786-O stable cell lines were lysed and immunoprecipitated with an anti-HA antibody. The bound proteins were resolved by SDS-PAGE
and immunoblotted with an anti-Cul2 antibody (upper panel) or an anti-HA antibody (lower panel). (C) In vitro ubiquitylation assay was
performed where plasmids encoding pVHL(WT), pVHL(C162F), or pVHL(RRR) were in vitro translated and mixed with 35S-labeled Gal4-HA-
tagged HIF- ODD. The reaction mixture was immunoprecipitated with an anti-Gal4 antibody, and the bound proteins were resolved by
SDS-PAGE and visualized by autoradiography. (D) Equal amounts of the whole-cell extracts prepared from the indicated 786-O stable subclones
were separated on SDS-PAGE and immunoblotted with an anti-GLUT1 (upper panel) or an anti-HA (lower panel) antibody. IP, immunopre-
cipitated; AR, autoradiography.
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pVHL mutants. U2OS cells were transfected with plasmids
encoding these mutants in combination with T7-NEDD8 (Fig.
2B). pVHL(KRR) became neddylated at a level comparable to
that of pVHL(WT). However, pVHL(RKR) showed negligible
modification by NEDD8, while pVHL(RRK) showed only a
slight modification. These results suggest that lysine 159 is the
major acceptor site of NEDD8 (see also Fig. 7A).
Neddylation of pVHL is not required for E3 function. To
assess whether neddylation of pVHL is required for forming
an E3 VEC complex, U2OS cells were transfected with
HA-tagged pVHL(WT), pVHL(C162F), and pVHL(RRR).
pVHL(C162F) served as a negative control because this is a
disease-causing mutant that fails to bind elongin C and hence
does not form an E3 VEC complex (16, 22, 25). pVHL(RRR)
was capable of binding elongins B and C and Cul2 (Fig. 3A and
B). We next asked whether neddylation of pVHL was required
for the ubiquitylation of the HIF- subunit. S100 extracts made
from 786-O RCC cells devoid of pVHL supplemented with in
vitro-translated empty plasmid alone (MOCK) or tumor-
derived pVHL(C162F) failed to support the ubiquitylation of
HIF-1(ODD) (Fig. 3C). However, S100 extracts supple-
mented with either in vitro-translated pVHL(WT) or pVHL-
(RRR) ubiquitylated HIF-1(ODD) (Fig. 3C). Furthermore,
multiple 786-O subclones stably transfected with pVHL-
(RRR), like stable subclones expressing pVHL(WT), down-
regulated the expression of the HIF-targeted gene GLUT1
under normal oxygen tension (Fig. 3D). As expected, 786-O
subclones expressing empty plasmid alone (MOCK) or
pVHL(C162F) showed overexpression of GLUT1 even under
normoxia (Fig. 3D). These results demonstrate that neddyla-
FIG. 4. pVHL(RRR) shows reduced binding to fibronectin, and RCC cells expressing pVHL(RRR) show decreased fibronectin deposition and
assembly. (A) The indicated 786-O subclones were radiolabeled with [35S]methionine. Cells were lysed and immunoprecipitated with an anti-HA
antibody. The bound proteins were resolved with SDS-PAGE and visualized by autoradiography. (B) The amount of fibronectin deposited by the
indicated 786-O subclones was measured by ELISA at 405 nm. (C) Fibronectin immunofluorescence was performed on 786-MOCK, 786-WT, and
786-RRR subclones by using rabbit anti-fibronectin-rhodamine staining. IP, immunoprecipitated; OD, optical density; AR, autoradiography.
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tion of pVHL is not required for the proper E3 ligase activity
of VEC.
Neddylation of pVHL is required for extracellular fibronec-
tin matrix assembly. To ascertain whether the neddylation of
pVHL is required for proper fibronectin matrix assembly, we
first asked whether pVHL(RRR) can bind fibronectin. 786-O
cells stably expressing HA-pVHL(WT), HA-pVHL(C162F),
and HA-pVHL(RRR) were metabolically labeled with
[35S]methionine. Cells were lysed, immunoprecipitated with an
anti-HA antibody, and resolved with SDS-PAGE (Fig. 4A). As
expected, pVHL(WT) bound fibronectin, while a disease-caus-
ing  domain pVHL(C162F) mutant failed to bind fibronectin.
pVHL(RRR) showed negligible binding to fibronectin (Fig.
4A). Furthermore, 786-O cells expressing pVHL(RRR) depos-
ited a small quantity of fibronectin, which was comparable to
that of 786-O expressing plasmid alone (MOCK) or pVHL
(C162F) (Fig. 4B). 786-O cells expressing pVHL(WT) depos-
ited high concentrations of fibronectin (Fig. 4B) and were
capable of forming strands of extracellular fibronectin (Fig.
4C). However, pVHL(RRR)-expressing cells failed to form
fibrillar fibronectin arrays in the extracellular compartment
(Fig. 4C).
RCC cells expressing pVHL(RRR) grow as compact, undif-
ferentiated spheroids. It has been previously documented that
786-O cells devoid of pVHL grow as very compact and cohe-
sive spheroids, while pVHL(WT)-reconstituted 786-O cells
grow as loosely arranged spheroids that form a network of
tubular and trabecular structures within the spheroid (17).
Importantly, the morphological changes seen with the
pVHL(WT) spheroids were associated with the deposition of
fibronectin in the extracellular space, a feature that was absent
in disease-causing pVHL-expressing spheroids (17). Concor-
dantly, multiple pVHL(RRR)-expressing 786-O subclones,
which are defective in forming the fibronectin matrix, grew as
compact spheroids and closely resembled 786-O cells devoid of
functional pVHL (Fig. 5). These results strongly suggest that
the NEDD8 modification of pVHL is necessary for normal
growth in three-dimensional space that mimics the in vivo
multicellular growth conditions.
pVHL(RRR) fails to suppress tumor formation in SCID
mouse xenograft assay. Multiple 786-O subclones expressing
pVHL(WT), pVHL(RRR), or plasmid alone (MOCK) were
injected intramuscularly into the left hind legs of SCID mice.
Tumor-take and tumor size were monitored and measured
weekly (Fig. 6). After approximately 1 month, as expected,
786-MOCK cells formed tumors (4 of 4), while mice injected
with multiple 786-WT subclones were tumor free (0 of 8) (Fig.
6A and B). However, most of the mice injected with multiple
786-RRR subclones developed tumors (11 of 12) (Fig. 6B). It
should be noted that the average 786-RRR tumor weight was
slightly lower than that of 786-MOCK tumors (data not
shown). These results demonstrate that in the absence of
NEDD8 modification of pVHL, which affects the assembly of
extracellular fibronectin matrix, an intact HIF pathway is in-
sufficient to suppress tumor formation in SCID mice.
The VHL type 2C-causing mutant pVHL(K159E) is not
modified by NEDD8 but forms an active E3 ligase complex and
fails to bind fibronectin. Individuals who inherit the
pVHL(K159E) mutant allele are predisposed to develop VHL
type 2C disease (pheochromocytoma without the other stig-
mata of the VHL disease) (32). Our findings above strongly
suggest that K159 is the major acceptor site of NEDD8, and
hence we asked whether this type 2C-causing mutant is inca-
pable of being conjugated by NEDD8. U2OS cells were
transfected with plasmids encoding HA-pVHL(WT), HA-
pVHL(RRR), HA-pVHL(K159E), and HA-pVHL(KRR) in
combination with T7-NEDD8. The cells were then lysed and
were immunoprecipitated and immunoblotted with an an-
ti-HA antibody (Fig. 7A, lower panel). pVHL(WT), as ex-
pected, and pVHL(KRR) were modified by NEDD8. How-
ever, pVHL(RRR), as expected, and pVHL(K159E) failed to
be conjugated with NEDD8 (Fig. 7A). This demonstrates that
the K at position 159 is the major, or perhaps the sole, acceptor
site of NEDD8, and in accord, the VHL type 2C-associated
pVHL(K159E) mutant fails to be modified by NEDD8.
pVHL(K159E), which contains a mutation in the  domain,
still retained the ability to bind Cul2 (Fig. 7A, upper panel), as
well as elongins B and C, albeit with weaker affinity (data not
shown). Thus, we asked whether pVHL(K159E) can support
the ubiquitylation of HIF-1(ODD). S100 extracts made from
786-O RCC cells devoid of pVHL supplemented with in vitro-
translated empty plasmid alone (MOCK) or disease-causing
FIG. 5. Neddylation of pVHL affects the growth of RCC cells in a
three-dimensional growth assay. Digital images (50) of the indicated
and representative 786-O subclones grown as spheroids in semisolid
media were captured on day 3. Two 786-MOCK, two 786-WT, and
four 786-RRR subclones were tested.
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pVHL(C162F), which does not form an E3 ligase complex,
failed to support the ubiquitylation of HIF-1(ODD) (Fig.
7B). However, S100 extracts supplemented with either in vitro-
translated pVHL(WT), pVHL(RRR), pVHL(K159E), or
pVHL(KRR) ubiquitylated HIF-1(ODD) (Fig. 7B), and con-
cordantly, 786-O stable subclones expressing pVHL(WT),
pVHL(K159E), and pVHL(KRR) down-regulated the expres-
sion of the HIF-targeted gene product GLUT1 (Fig. 7C).
To ascertain whether pVHL(K159E) is able to support bind-
ing to fibronectin, 786-O cells stably expressing empty plasmid
alone (MOCK), HA-pVHL(WT), HA-pVHL(K159E), and
HA-pVHL(KRR) were metabolically labeled with [35S]methi-
onine. The cells were lysed, immunoprecipitated with an an-
ti-HA antibody, and resolved with SDS-PAGE (Fig. 7D).
pVHL(WT), as expected, and pVHL(KRR) bound fibronec-
tin. However, pVHL(K159E) failed to bind fibronectin (Fig.
7D). These results, taken together, suggest that although
NEDD8-modification of pVHL is not required for forming an
active E3 ligase complex, it is required for the interaction with
fibronectin.
DISCUSSION
VHL disease can be categorized by using a phenotype-based
classification system (21). Type 1 patients develop hemangio-
blastoma (central nervous system and retina) and RCC. Type
2A patients develop hemangioblastoma and pheochromocy-
toma, while type 2B patients develop hemangioblastoma,
pheochromocytoma, and RCC. Type 2C patients develop only
pheochromocytoma. pVHL has two functional domains:  and
 (22, 31). The  domain is required for binding elongin C,
which allows the nucleation of the E3 complex. The  domain
acts as a substrate recognition and binding region. Most dis-
FIG. 6. pVHL(RRR) fails to suppress tumor formation in SCID mouse xenograft assay. (A) Tumor-take in representative mice injected with
786-O cells stably expressing either MOCK, pVHL(WT), or pVHL(RRR). The left hind leg was shaved and the tumor was resected (shown on
the right). N/A, not applicable since no tumors were found on mice injected with 786-pVHL(WT) subclones; bar, 1 cm. (B) A graph of tumor
growth over time in mice injected with the indicated 786-O stable subclones. One 786-MOCK, two 786-WT, and three 786-RRR subclones were
tested, and four mice were injected per subclone. The total numbers of mice that grew tumors are indicated on the right.
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ease-causing mutations on pVHL affect the ability of pVHL
either to form an active E3 ligase complex or to bind its
substrates (14). Thus, the development of VHL disease has
been strongly suggested to be due to the failure of the pVHL’s
E3 ligase activity, implying that normal HIF regulation is crit-
ical for the tumor suppressor function of pVHL.
However, the notion of HIF regulation being the sole essen-
tial function of pVHL that is critical for tumor suppression
FIG. 7. VHL type 2C-causing pVHL(K159E) mutant is capable of NEDD8 conjugation and forms an active E3 ligase but fails to bind
fibronectin. (A) U2OS cells were transfected with plasmids encoding T7-NEDD8 and the indicated HA-pVHL. The cells were lysed and
immunoprecipitated with an anti-HA antibody. Bound proteins were resolved by SDS-PAGE and immunoblotted with an anti-Cul2 antibody
(upper panel) or an anti-HA antibody (lower panel). (B) In vitro ubiquitylation assay was performed where plasmids encoding the indicated
HA-pVHL were in vitro translated and mixed with 35S-labeled Gal4-HA-HIF- ODD. The reaction mixture was immunoprecipitated with an
anti-Gal4 antibody, and the bound proteins were resolved by SDS-PAGE and visualized by autoradiography. (C) Equal amounts of the whole-cell
extracts prepared from the indicated 786-O stable subclones were separated with SDS-PAGE and immunoblotted with an anti-GLUT1 (upper
panel) or an anti-HA (lower panel) antibody. (D) The indicated 786-O subclones were radiolabeled with [35S]methionine. Cells were lysed and
immunoprecipitated with an anti-HA antibody. The bound proteins were resolved with SDS-PAGE and visualized by autoradiography. IP,
immunoprecipitated; AR, autoradiography.
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came into question when type 2C disease-causing pVHL mu-
tants were shown to properly regulate HIF but failed to pro-
mote the assembly of fibronectin (1, 9). Here, we show that
another type 2C-causing pVHL(K159E) is not modified by
NEDD8 but is capable of ubiquitylating the ODD of HIF-1.
Moreover, this neddylation-defective pVHL(K159E) fails to
bind fibronectin. The potential significance of fibronectin as-
sembly for the ability of pVHL to suppress tumor development
is further inferred by the finding that every disease-causing
pVHL mutant, covering the entire spectrum of VHL disease
(i.e., types 1, 2A, 2B, and 2C), tested to date has failed to bind
fibronectin (1, 9, 23). Furthermore, Clifford and colleagues
demonstrated that the impairment of HIF regulation was po-
tentially required for hemangioblastoma and RCC develop-
ment, while the loss of fibronectin binding was observed for all
disease-causing pVHL mutants (1). However, it should be
noted that the functional significance of the majority of pVHL
mutations has not been formally defined.
Dysregulated ECM, as well as abnormal cell-matrix interac-
tions, are hallmarks of solid tumors (28). Alterations in the
fibronectin component of the ECM have been correlated with
cellular transformation (6, 7, 28). Conversely, multimeric
forms of fibronectin have been shown to promote differentia-
tion and suppress the proliferative and metastatic potentials of
transformed cells in various model systems (27). Here, we have
shown that a small fraction of pVHL is covalently conjugated
by NEDD8. In the absence of such modifications, pVHL failed
to bind fibronectin, and the assembly of extracellular fibronec-
tin was severely compromised. It should be noted that fi-
bronectin matrix assembly is also dependent on other cellular
events such as the interplay between fibronectin receptors and
cytoskeletal organization (29, 30). Furthermore, since disease-
causing pVHL mutants with intact triple lysine residues fail to
bind fibronectin, there are likely other mechanisms that influ-
ence the assembly of fibronectin. Moreover, the potential re-
quirement of the E3 ligase activity of VEC for proper fibronec-
tin assembly has not been determined. Understanding the
precise underlying mechanisms, including the NEDD8 modi-
fication of pVHL, that influence the proper extracellular fi-
bronectin matrix assembly will be important in understanding
the initial steps of the VHL disease progression.
The E3 activity of VEC was demonstrated to be independent
of pVHL neddylation status. Thus, the E3 ligase function was
separable from the fibronectin assembly function by blocking
the NEDD8 modification of pVHL. In other words, RCC cells
expressing nonneddylateable pVHL, while retaining the ability
to regulate HIF, grew as compact, undifferentiated spheroids
and formed tumors in SCID mice. Thus, an intact HIF pathway
in the absence of proper pVHL-dependent fibronectin regula-
tion was insufficient to prevent tumorigenesis.
The specific subtype of VHL disease may depend on the
failure of pVHL to perform various functions ascribed to
pVHL, including ubiquitylation of HIF-1, -2, or -3, as well as
atypical protein kinase C, the deubiquitylating enzyme VDU-1,
and the homeodomain-containing protein Jade-1 (2, 15, 19, 20,
22, 26, 33). pVHL has also been shown to affect transcription
by binding Sp1 and the KRAB-A domain protein (3, 16).
Recently, pVHL was found to associate with microtubules to
prevent depolymerization and, in effect, regulated the stability
of microtubules (8). Our results, in light of the fact that every
disease-causing pVHL mutant fails to bind fibronectin,
strongly suggest that a defect in fibronectin assembly is a com-
mon event in VHL-associated tumorigenesis. Further mecha-
nistic insights into the various ascribed functions of pVHL will
undoubtedly aid in unraveling the mystery of the genotype-
phenotype correlation that exists in VHL disease.
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